60f990a3aa40346ca988941d dapagliflozin-in-patients-with-cardiometabolic-risk-factors-hospitalised-with-covid-19-dare-19-a-randomised-double-blind-placebo-controlled-phase-3-trial 2021-07-22T16:40:06.591Z 5e283dc93b5e750642253e53 0a7bdd5b-d027-48a9-813f-707b8f7e2d8f f48a5fc4-8228-47ec-ba84-e6c8e22ded59 mas_evidence_types:Randomised%20controlled%20trials Primary research RCT (n=1250) found treatment with dapagliflozin in this group, did not result in statistically significant risk reduction in organ dysfunction or death (11.2% vs. 13.8%, respectively, p=0.17) or improvement in clinical recovery (87.5% vs, 85.1%, p=0.14), but was well tolerated. <p>A commentary notes some lessons can be learned from this trial:</p> <ul> <li>Dapagliflozin can be safely used in patients with cardiometabolic risk factors who were hospitalised with COVID-19 pneumonia, regardless of their diabetes status.</li> <li>Although findings of dapagliflozin failed to show efficacy in the acute setting, SGLT2 inhibitors have a promising future not only in patients with diabetes but also in patients with chronic cardiovascular disease, chronic kidney disease, and perhaps even in asymptomatic people.</li> <li>A trial done in the middle of a pandemic in such a short time is not an easy task and the authors should take credit for adding evidence when it was most needed.</li> <li>Regardless of the significance of the primary hypothesis, the authors adequately tested whether dapagliflozin was effective and safe in hospitalised patients with cardiometabolic risk factors and COVID-19.</li> </ul> https://www.medicinesresources.nhs.uk/dapagliflozin-in-patients-with-cardiometabolic-risk-factors-hospitalised-with-covid-19-dare-19-a-randomised-double-blind-placebo-controlled-phase-3-trial.html <p><a href="https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00206-0/fulltext">Comment</a></p> https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00180-7/fulltext 2021-07-21T00:00:00Z 2021-07-22T15:37:07.126Z